GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004217613 | Lung | AIS | regulation of protein catabolic process | 92/1849 | 391/18723 | 1.34e-15 | 3.91e-12 | 92 |
GO:000989613 | Lung | AIS | positive regulation of catabolic process | 103/1849 | 492/18723 | 9.59e-14 | 1.86e-10 | 103 |
GO:004573213 | Lung | AIS | positive regulation of protein catabolic process | 60/1849 | 231/18723 | 1.47e-12 | 2.14e-09 | 60 |
GO:003133113 | Lung | AIS | positive regulation of cellular catabolic process | 89/1849 | 427/18723 | 6.12e-12 | 4.46e-09 | 89 |
GO:190336213 | Lung | AIS | regulation of cellular protein catabolic process | 62/1849 | 255/18723 | 1.37e-11 | 6.13e-09 | 62 |
GO:190336413 | Lung | AIS | positive regulation of cellular protein catabolic process | 41/1849 | 155/18723 | 2.79e-09 | 4.92e-07 | 41 |
GO:000689812 | Lung | AIS | receptor-mediated endocytosis | 50/1849 | 244/18723 | 4.47e-07 | 3.52e-05 | 50 |
GO:000165511 | Lung | AIS | urogenital system development | 63/1849 | 338/18723 | 5.46e-07 | 4.08e-05 | 63 |
GO:000182211 | Lung | AIS | kidney development | 53/1849 | 293/18723 | 1.04e-05 | 4.25e-04 | 53 |
GO:007200111 | Lung | AIS | renal system development | 54/1849 | 302/18723 | 1.21e-05 | 4.71e-04 | 54 |
GO:006056211 | Lung | AIS | epithelial tube morphogenesis | 57/1849 | 325/18723 | 1.27e-05 | 4.78e-04 | 57 |
GO:006145812 | Lung | AIS | reproductive system development | 70/1849 | 427/18723 | 1.52e-05 | 5.50e-04 | 70 |
GO:004860811 | Lung | AIS | reproductive structure development | 69/1849 | 424/18723 | 2.23e-05 | 7.42e-04 | 69 |
GO:000184111 | Lung | AIS | neural tube formation | 23/1849 | 102/18723 | 1.24e-04 | 2.82e-03 | 23 |
GO:001402011 | Lung | AIS | primary neural tube formation | 21/1849 | 94/18723 | 2.75e-04 | 5.19e-03 | 21 |
GO:000184311 | Lung | AIS | neural tube closure | 20/1849 | 88/18723 | 2.99e-04 | 5.54e-03 | 20 |
GO:006060611 | Lung | AIS | tube closure | 20/1849 | 89/18723 | 3.50e-04 | 6.28e-03 | 20 |
GO:000183811 | Lung | AIS | embryonic epithelial tube formation | 24/1849 | 121/18723 | 6.82e-04 | 1.02e-02 | 24 |
GO:002191511 | Lung | AIS | neural tube development | 28/1849 | 152/18723 | 8.81e-04 | 1.19e-02 | 28 |
GO:00163311 | Lung | AIS | morphogenesis of embryonic epithelium | 27/1849 | 147/18723 | 1.13e-03 | 1.45e-02 | 27 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRP2 | SNV | Missense_Mutation | | c.2974N>T | p.Pro992Ser | p.P992S | P98164 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | | SD |
LRP2 | SNV | Missense_Mutation | | c.9232C>G | p.His3078Asp | p.H3078D | P98164 | protein_coding | tolerated(0.95) | benign(0.041) | TCGA-DG-A2KM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
LRP2 | SNV | Missense_Mutation | | c.11757C>G | p.His3919Gln | p.H3919Q | P98164 | protein_coding | tolerated(0.68) | benign(0.018) | TCGA-DS-A0VK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
LRP2 | SNV | Missense_Mutation | | c.9627N>C | p.Leu3209Phe | p.L3209F | P98164 | protein_coding | deleterious(0) | possibly_damaging(0.814) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
LRP2 | SNV | Missense_Mutation | | c.7475C>T | p.Ser2492Phe | p.S2492F | P98164 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LRP2 | SNV | Missense_Mutation | | c.6642G>T | p.Lys2214Asn | p.K2214N | P98164 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP2 | SNV | Missense_Mutation | | c.7783N>T | p.Ala2595Ser | p.A2595S | P98164 | protein_coding | tolerated(0.09) | benign(0.005) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
LRP2 | SNV | Missense_Mutation | novel | c.12319G>A | p.Gly4107Arg | p.G4107R | P98164 | protein_coding | deleterious(0.05) | possibly_damaging(0.802) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
LRP2 | SNV | Missense_Mutation | | c.6548N>C | p.Val2183Ala | p.V2183A | P98164 | protein_coding | deleterious(0) | benign(0.416) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LRP2 | SNV | Missense_Mutation | | c.5331N>G | p.Ile1777Met | p.I1777M | P98164 | protein_coding | deleterious(0) | possibly_damaging(0.487) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |